This viewpoint offers expert guidance for the use of COVID-19 convalescent plasma (CCP) to treat immune compromised patients with acute or protracted COVID-19,
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
Key Points. Quantification of the primary myeloma cell surface proteome enables unbiased discovery of novel therapeutic targets.Targeting SEMA4A using an a
Amplification of chromosome 1q (chr1q-amp) is an adverse prognostic feature in multiple myeloma (MM). In this Plenary paper, Trasanidis and colleagues perf
As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma…
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Click on the article title to read more.
EHA Library; Müller-Tidow C. Jun 10 2022; 357146;
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…
Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…
